Differential role of Interleukin-1 and Interleukin-6 in K-Ras-driven pancreatic carcinoma undergoing mesenchymal transition

References

• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74. doi:10.1016/j.cell.2011.02.013. PMID:21376230
   PubMed Web of Science ®Google Scholar
• Zhong Z, Sanchez-Lopez E, Karin M. Autophagy, inflammation, and immunity: a troika governing cancer and its treatment. Cell. 2016;166:288–98. doi:10.1016/j.cell.2016.05.051. PMID:27419869
   PubMed Web of Science ®Google Scholar
• Coussens LM, Zitvogel L, Palucka AK. Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science. 2013;339:286–91. doi:10.1126/science.1232227. PMID:23329041
   PubMed Web of Science ®Google Scholar
• Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer. 2013;13:759–71. doi:10.1038/nrc3611. PMID:24154716
   PubMed Web of Science ®Google Scholar
• Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017;14:399–416. doi:10.1038/nrclinonc.2016.217. PMID:28117416
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–44. doi:10.1038/nature07205. PMID:18650914
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67:7–30. doi:10.3322/caac.21387.
   PubMed Web of Science ®Google Scholar
• Hruban RH. Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Res. 2006;66:95–106. doi:10.1158/0008-5472.CAN-05-2168. PMID:16397221
   PubMed Web of Science ®Google Scholar
• Matsuo Y, Campbell PM, Brekken RA, Sung B, Ouellette MM, Fleming JB, Aggarwal BB, Der CJ, Guha S. K-Ras promotes angiogenesis mediated by immortalized human pancreatic epithelial cells through mitogen-activated protein kinase signaling pathways. Mol Cancer Res. 2009;7:799–808. doi:10.1158/1541-7786.MCR-08-0577. PMID:19509115
   PubMed Web of Science ®Google Scholar
• Guerra CC, Schuhmacher AJA, Cañamero MM, Grippo PJP, Verdaguer LL, Pérez-Gallego LL, Dubus PP, Sandgren EPE, Barbacid MM. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell. 2007;11:12–2. doi:10.1016/j.ccr.2007.01.012.
   Web of Science ®Google Scholar
• Sparmann A, Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell. 2004;6:447–58. doi:10.1016/j.ccr.2004.09.028. PMID:15542429
   PubMed Web of Science ®Google Scholar
• Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the future. Immunity. 2013;39:1003–18. doi:10.1016/j.immuni.2013.11.010. PMID:24332029
   PubMed Web of Science ®Google Scholar
• Voronov E, Shouval DS, Krelin Y, Cagnano E, Benharroch D, Iwakura Y, Dinarello CA, Apte RN. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci USA. 2003;100:2645–50. doi:10.1073/pnas.0437939100. PMID:12598651
   PubMed Web of Science ®Google Scholar
• Daniluk J, Liu Y, Deng D, Chu J, Huang H, Gaiser S, Cruz-Monserrate Z, Wang H, Ji B, Logsdon CD. An NF-κB pathway-mediated positive feedback loop amplifies Ras activity to pathological levels in mice. J Clin Invest. 2012;122:1519–28. doi:10.1172/JCI59743. PMID:22406536
   PubMed Web of Science ®Google Scholar
• Huang H, Daniluk J, Liu Y, Chu J, Li Z, Ji B, Logsdon CD. Oncogenic K-Ras requires activation for enhanced activity. Oncogene. 2013;33:532–5.
   Web of Science ®Google Scholar
• Ling J, Kang Y, Zhao R, Xia Q, Lee D-F, Chang Z, Li J, Peng B, Fleming JB, Wang H, et al. KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell. 2012;21:105–20. doi:10.1016/j.ccr.2011.12.006. PMID:22264792
   PubMed Web of Science ®Google Scholar
• Wang Z, Ali S, Banerjee S, Bao B, Li Y, Azmi AS, Korc M, Sarkar FH. Activated K-Ras and INK4 a/Arf deficiency promote aggressiveness of pancreatic cancer by induction of EMT consistent with cancer stem cell phenotype. J Cell Physiol. 2013;228:556–62. doi:10.1002/jcp.24162. PMID:22806240
   PubMed Web of Science ®Google Scholar
• Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, DePinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2006;20:1218–49. doi:10.1101/gad.1415606. PMID:16702400
   PubMed Web of Science ®Google Scholar
• Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119:1420–8. doi:10.1172/JCI39104. PMID:19487818
   PubMed Web of Science ®Google Scholar
• Tsuji T, Ibaragi S, Hu G-F. Epithelial-mesenchymal transition and cell cooperativity in metastasis. Cancer Res. 2009;69:7135–9. doi:10.1158/0008-5472.CAN-09-1618. PMID:19738043
   PubMed Web of Science ®Google Scholar
• Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, Reichert M, Beatty GL, Rustgi AK, Vonderheide RH, et al. EMT and dissemination precede pancreatic tumor formation. Cell. 2012;148:349–61. doi:10.1016/j.cell.2011.11.025. PMID:22265420
   PubMed Web of Science ®Google Scholar
• Rucki AA, Foley K, Zhang P, Xiao Q, Kleponis J, Wu AA, Sharma R, Mo G, Liu A, Van Eyk J, et al. Heterogeneous stromal signaling within the tumor microenvironment controls the metastasis of pancreatic cancer. Cancer Res. 2017;77:41–52. doi:10.1158/0008-5472.CAN-16-1383. PMID:27821486
   PubMed Web of Science ®Google Scholar
• López-Novoa JM, Nieto MA. Inflammation and EMT: an alliance towards organ fibrosis and cancer progression. EMBO Mol Med. 2009;1:303–14. doi:10.1002/emmm.200900043. PMID:20049734
   PubMed Web of Science ®Google Scholar
• Wu Y, Deng J, Rychahou PG, Qiu S, Evers BM, Zhou BP. Stabilization of snail by NF-kappaB is required for inflammation-induced cell migration and invasion. Cancer Cell. 2009;15:416–28. doi:10.1016/j.ccr.2009.03.016. PMID:19411070
   PubMed Web of Science ®Google Scholar
• Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15:178–96. doi:10.1038/nrm3758. PMID:24556840
   PubMed Web of Science ®Google Scholar
• Carbone C, Moccia T, Zhu C, Paradiso G, Budillon A, Chiao PJ, Abbruzzese JL, Melisi D. Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype. Clin Cancer Res. 2011;17:5822–32. doi:10.1158/1078-0432.CCR-11-1185. PMID:21737511
   PubMed Web of Science ®Google Scholar
• Suarez-Carmona M, Lesage J, Cataldo D, Gilles C. EMT and inflammation: inseparable actors of cancer progression. Mol Oncol. 2017;11:805–23. doi:10.1002/1878-0261.12095. PMID:28599100
   PubMed Web of Science ®Google Scholar
• Khalafalla FG, Khan MW. Inflammation and epithelial-mesenchymal transition in pancreatic ductal adenocarcinoma: fighting against multiple opponents. Cancer Growth Metastasis. 2017;10:1179064417709287. PMID:28579826
   PubMed Web of Science ®Google Scholar
• Mejlvang J, Kriajevska M, Vandewalle C, Chernova T, Sayan AE, Berx G, Mellon JK, Tulchinsky E. Direct repression of cyclin D1 by SIP1 attenuates cell cycle progression in cells undergoing an epithelial mesenchymal transition. Mol Biol Cell. 2007;18:4615–24. doi:10.1091/mbc.E07-05-0406. PMID:17855508
   PubMed Web of Science ®Google Scholar
• Wan L, Pantel K, Kang Y. Tumor metastasis: moving new biological insights into the clinic. Nat Med. 2013;19:1450–64. doi:10.1038/nm.3391. PMID:24202397
   PubMed Web of Science ®Google Scholar
• Morris JP, Wang SC, Hebrok M. KRAS, Hedgehog, wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat Rev Cancer. 2010;10:683–95. doi:10.1038/nrc2899. PMID:20814421
   PubMed Web of Science ®Google Scholar
• Rodriguez-Viciana P, Tetsu O, Oda K, Okada J, Rauen K, McCormick F. Cancer targets in the Ras pathway. Cold Spring Harb Symp Quant Biol. 2005;70:461–7. doi:10.1101/sqb.2005.70.044. PMID:16869784
   PubMedGoogle Scholar
• Lewis AM, Varghese S, Xu H, Alexander HR. Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. J Transl Med. 2006;4:48. doi:10.1186/1479-5876-4-48. PMID:17096856
   PubMed Web of Science ®Google Scholar
• Jonckheere N, Vasseur R, Van Seuningen I. The cornerstone K-RAS mutation in pancreatic adenocarcinoma: From cell signaling network, target genes, biological processes to therapeutic targeting. Critical Rev Oncol Hematol. 2017;111:7–19. doi:10.1016/j.critrevonc.2017.01.002.
   PubMed Web of Science ®Google Scholar
• Collins MA, Brisset J-C, Zhang Y, Bednar F, Pierre J, Heist KA, Galbán CJ, Galbán S, di Magliano MP. Metastatic pancreatic cancer is dependent on oncogenic Kras in mice. PLoS One. 2012;7:e49707. doi:10.1371/journal.pone.0049707. PMID:23226501
   PubMed Web of Science ®Google Scholar
• Xu W, Wang Z, Zhang W, Qian K, Li H, Kong D, Li Y, Tang Y. Mutated K-ras activates CDK8 to stimulate the epithelial-to-mesenchymal transition in pancreatic cancer in part via the Wnt/β-catenin signaling pathway. Cancer Letters. 2015;356:613–27. doi:10.1016/j.canlet.2014.10.008. PMID:25305448
   PubMed Web of Science ®Google Scholar
• Tjomsland V, Spångeus A, Välilä J, Sandström P, Borch K, Druid H, Falkmer S, Falkmer U, Messmer D, Larsson M. Interleukin 1α sustains the expression of inflammatory factors in human pancreatic cancer microenvironment by targeting cancer-associated fibroblasts. Neoplasia. 2011;13:664–75. doi:10.1593/neo.11332. PMID:21847358
   PubMed Web of Science ®Google Scholar
• Steele CW, Jamieson NB, Evans TRJ, McKay CJ, Sansom OJ, Morton JP, Carter CR. Exploiting inflammation for therapeutic gain in pancreatic cancer. Br J Cancer. 2013;108:997–1003. doi:10.1038/bjc.2013.24. PMID:23385734
   PubMed Web of Science ®Google Scholar
• Piro G, Simionato F, Carbone C, Frizziero M, Malleo G, Zanini S, Casolino R, Santoro R, Mina MM, Zecchetto C, et al. A circulating T H2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma. OncoImmunology. 2017;6(9):e1322242. doi:10.1080/2162402X.2017.1322242. PMID:28932629
   PubMed Web of Science ®Google Scholar
• Cataisson CC, Salcedo RR, Hakim SS, Moffitt BAB, Wright LL, Yi MM, Stephens RR, Dai R-MR, Lyakh LL, Schenten DD, et al. IL-1R-MyD88 signaling in keratinocyte transformation and carcinogenesis. J Exp Med. 2012;209:1689–702. doi:10.1084/jem.20101355. PMID:22908325
   PubMed Web of Science ®Google Scholar
• Niu J, Li Z, Peng B, Chiao PJ. Identification of an autoregulatory feedback pathway involving interleukin-1alpha in induction of constitutive NF-kappaB activation in pancreatic cancer cells. J Biol Chem. 2004;279:16452–62. doi:10.1074/jbc.M309789200. PMID:14679213
   PubMed Web of Science ®Google Scholar
• Zhang D, Li L, Jiang H, Knolhoff BL, Lockhart AC, Wang-Gillam A, DeNardo DG, Ruzinova MB, Lim K-H. Constitutive IRAK4 activation underlies poor prognosis and chemoresistance in pancreatic ductal adenocarcinoma. Clin Cancer Res. 2017;23:1748–59. doi:10.1158/1078-0432.CCR-16-1121. PMID:27702822
   PubMed Web of Science ®Google Scholar
• Bang D, Wilson W, Ryan M, Yeh JJ, Baldwin AS. GSK-3α promotes oncogenic KRAS function in pancreatic cancer via TAK1-TAB stabilization and regulation of noncanonical NF-κB. Cancer Discovery. 2013;3:690–703. doi:10.1158/2159-8290.CD-12-0541. PMID:23547054
   PubMed Web of Science ®Google Scholar
• Li C-W, Xia W, Huo L, Lim S-O, Wu Y, Hsu JL, Chao C-H, Yamaguchi H, Yang N-K, Ding Q, et al. Epithelial-mesenchymal transition induced by TNF-α requires NF-κB-mediated transcriptional upregulation of Twist1. Cancer Res. 2012;72:1290–300. doi:10.1158/0008-5472.CAN-11-3123. PMID:22253230
   PubMed Web of Science ®Google Scholar
• Pettersson AT, Laurencikiene J, Mejhert N, Näslund E, Bouloumié A, Dahlman I, Arner P, Rydén M. A possible inflammatory role of twist1 in human white adipocytes. Diabetes. 2010;59:564–71. doi:10.2337/db09-0997. PMID:20007935
   PubMed Web of Science ®Google Scholar
• Qin Q, Xu Y, He T, Qin C, Xu J. Normal and disease-related biological functions of Twist1 and underlying molecular mechanisms. Cell Res. 2012;22:90–106. doi:10.1038/cr.2011.144. PMID:21876555
   PubMed Web of Science ®Google Scholar
• Holmer R, Goumas FA, Waetzig GH, Rose-John S, Kalthoff H. Interleukin-6: a villain in the drama of pancreatic cancer development and progression. HBPD INT. 2014;13:371–80. PMID:25100121
   PubMed Web of Science ®Google Scholar
• Lesina M, Kurkowski MU, Ludes K, Rose-John S, Treiber M, Klöppel G, Yoshimura A, Reindl W, Sipos B, Akira S, et al. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell. 2011;19:456–69. doi:10.1016/j.ccr.2011.03.009. PMID:21481788
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Why not treat human cancer with interleukin-1 blockade? Cancer Metastasis Rev. 2010;29:317–29. doi:10.1007/s10555-010-9229-0. PMID:20422276
   PubMed Web of Science ®Google Scholar
• Jones SA, Scheller J, Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest. 2011;121:3375–83. doi:10.1172/JCI57158. PMID:21881215
   PubMed Web of Science ®Google Scholar
• Carbone C, Melisi D. NF-κB as a target for pancreatic cancer therapy. Expert Opin Ther Targets. 2012;16Suppl 2:S1–10. doi:10.1517/14728222.2011.645806. PMID:22443181
   PubMed Web of Science ®Google Scholar
• Apte RN, Voronov E. Immunotherapeutic approaches of IL-1 neutralization in the tumor microenvironment. J Leukoc Biol. 2017;102(2):293–306 doi:10.1189/jlb.3MR1216-523R. PMID:28522598
   PubMed Web of Science ®Google Scholar
• Arpin CC, Mac S, Jiang Y, Cheng H, Grimard M, Page BDG, Kamocka MM, Haftchenary S, Su H, Ball DP, et al. Applying small molecule signal transducer and activator of Transcription-3 (STAT3) Protein inhibitors as pancreatic cancer therapeutics. Mol Cancer Ther. 2016;15:794–805. doi:10.1158/1535-7163.MCT-15-0003. PMID:26873728
   PubMed Web of Science ®Google Scholar
• Lesina M, Wörmann SM, Morton J, Diakopoulos KN, Korneeva O, Wimmer M, Einwächter H, Sperveslage J, Demir IE, Kehl T, et al. RelA regulates CXCL1/CXCR2-dependent oncogene-induced senescence in murine Kras-driven pancreatic carcinogenesis. J Clin Invest. 2016;126:2919–32. doi:10.1172/JCI86477. PMID:27454298
   PubMed Web of Science ®Google Scholar
• Zhuang Z, Ju H-Q, Aguilar M, Gocho T, Li H, Iida T, Lee H, Fan X, Zhou H, Ling J, et al. IL1 receptor antagonist inhibits pancreatic cancer growth by abrogating NF-κB activation. Clin Cancer Res. 2016;22:1432–44. doi:10.1158/1078-0432.CCR-14-3382. PMID:26500238
   PubMed Web of Science ®Google Scholar
• Peters AHFM, Kubicek S, Mechtler K, O'Sullivan RJ, Derijck AAHA, Perez-Burgos L, Kohlmaier A, Opravil S, Tachibana M, Shinkai Y, et al. Partitioning and plasticity of repressive histone methylation states in mammalian chromatin. Mol Cell. 2003;12:1577–89. doi:10.1016/S1097-2765(03)00477-5. PMID:14690609
   PubMed Web of Science ®Google Scholar